Abstract
Background
Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are endogenous peptides, widely expressed in the central and peripheral nervous system. The adenylyl cyclase (AC)/cyclic AMP (cAMP) is their main intracellular signal transduction pathway. Numerous data suggest that PACAP and VIP have considerable neuroprotective potential, indicating the possibility for their use as new therapeutic strategies in stroke treatment. The aim of this study was to evaluate the effect of oxygen-glucose deprivation (OGD) – an established in vitro model for ischemic cell stress – on PACAP and VIP-evoked receptor-mediated cAMP generation in glial and neuronal cells, and to determine whether PACAP and VIP have neuroprotective activity under these conditions.
Methods
The formation of [3H]cAMP by PACAP, VIP and forskolin (a direct activator of AC) was measured in [3H]adenine prelabeled primary rat glial and neuronal cells under normoxia and OGD conditions. The effects of PACAP and VIP on cell viability were measured using the MTT conversion method, and were compared to tacrolimus (FK506), a well known neuroprotective agent.
Results
The OGD model inhibited the PACAP and VIP-induced cAMP formation in rat astrocytes and neurons. Incubation of neuronal cells with PACAP prevented OGD-induced cell death, more efficiently than VIP and FK506.
Conclusion
The obtained results showed that hypoxia/ischemia may trigger down-regulation of the brain AC-coupled PACAP/VIP receptors, with a consequent decrease of PACAP- and/or VIP-ergic-dependent cAMP-driven signaling. Moreover, our findings indicate that PACAP and VIP can prevent the deleterious effect of OGD on rat neuronal cells.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- AC:
-
adenylyl cyclase
- cAMP:
-
cyclic AMP
- CNS:
-
central nervous system
- CoCl2:
-
cobalt chloride
- DMEM:
-
Dulbecco’s Modified Eagle’s Medium
- ERK:
-
extracellular signal-regulated kinase
- FK506:
-
tacrolimus
- GFAP:
-
glial fibrillary acidic protein
- GHRH:
-
growth hormone-releasing hormone
- GPCRs:
-
receptors coupled with G proteins
- HIF-1:
-
hypoxia-inducible factor-1
- H2O2:
-
hydrogen peroxide
- MAP:
-
microtubule-associated protein-2 kinase
- MAP-2:
-
microtubule associating protein-2
- MTT:
-
3-(4,5-dimethylthazol-2-yl)-2,5-diphenyl-tetrazolium bromide
- OGD:
-
oxygen-glucose deprivation
- PACAP:
-
pituitary adenylate cyclase-activating polypeptide
- PHI:
-
peptide histidine-isoleucine
- PKA:
-
protein kinase A
- TBI:
-
traumatic brain injury
- VIP:
-
vasoactive intestinal peptide
References
Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009;5:355–69.
Chen Y, Samal B, Hamelink CR, Xiang CC, Chen Y, Chen M, et al. Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept 2006;137:4–19.
European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;5:457–507.
Faden AI, Stoica B. Neuroprotection: challenges and opportunities. Arch Neurol 2007;64:794–800.
Fisher M. New approaches to neuroprotective drug development. Stroke 2011;42(Suppl.):S24–7.
Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2000;52:269–324.
Dejda A, Sokołowska P, Nowak JZ. Neuroprotective potential of three neuro-peptides PACAP, VIP and PHI. Pharmacol Rep 2005;57:307–20.
Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009;61:283–357.
Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul Pept 2002;108:165–73.
Dejda A, Jolivel V, Bourgault S, Seaborn T, Fournier A, Vaudry H, et al. Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases. J Mol Neurosci 2008;36:26–37.
Li M, David C, Kikuta T, Somogyvari-Vigh A, Arimura A. Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38. J Mol Neurosci 2005;27:91–105.
Nakamachi T, Ohtaki H, Yofu S, Dohi K, Watanabe J, Mori H, et al. Endogenous pituitary adenylate cyclase activating polypeptide is involved in suppression of edema in the ischemic brain. Acta Neurochir Suppl 2010;106:43–6.
Ohtaki H, Nakamachi T, Dohi K, Shioda S. Role of PACAP in ischemic neural death. J Mol Neurosci 2008;36:16–25.
Jozwiak-Bebenista M, Dejda A, Nowak JZ. Effects of PACAP, VIP and related peptides on cyclic AMP formation in rat neuronal and astrocyte cultures and cerebral cortical slices. Pharmacol Rep 2007;59:414–20.
Nowak JZ, Jozwiak-Bebenista M, Bednarek K. Effects of PACAP and VIP on cyclic AMP formation in rat neuronal and astrocyte cultures under normoxic and hypoxic condition. Peptides 2007;28:1706–12.
Hertz L, Juurlink BHJ, Szuchet S. Cell cultures. In: Lajtha A, editor. Handbook of neurochemistry, vol. 8. New York: Plenum Press; 1985. p. 603–61.
Grasselli F, Basini G, Bussolatti S, Bianco F. Cobalt chloride, a hypoxia-mim-icking agent, modulates redox status and functional parameters of cultured swine granulose cells. Reprod Fertil Dev 2005;17:715–20.
Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993;82:3610–5.
Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem 1974;58:541–8.
Shimizu H, Daly JW, Creveling CR. A radioisotopic method for measuring the formation of adenosine 3’,5’-cyclic monophosphate in incubated slices of brain. J Neurochem 1969;16:1609–19.
Zhang YB, Wang X, Meister EA, Gong KR, Yan SC, Lu GW, et al. The effects of CoCl2 on HIF-1α protein under experimental conditions of autoprogressive hypoxia using mouse models. Int J Mol Sci 2014;15(June (6)):10999–1012.
Dejda A, Seaborn T, Bourgault S, Touzani O, Fournier A, Vaudry H, et al. PACAP and a novel stable analog protect rat brain from ischemia: insight into the mechanisms of action. Peptides 2011;32:1207–16.
Takano T, Oberheim N, Cotrina ML, Nedergaard M. Astrocytes and ischemic injury. Stroke 2009;40:8–12.
Vaudry D, Rousselle C, Basille M, Falluel-Morel A, Pamantung TF, Fontaine M, et al. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc Natl Acad Sci U S A 2002;99:6398–403.
Vaudry D, Pamantung TF, Basille M, Rousselle C, Fournier A, Vaudry H, et al. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 2002;15:1451–60.
Onoue S, Endo K, Ohshima K, Yajima T, Kashimoto K. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides 2002;23:1471–8.
Brenneman DE, Hauser J, Spong CY, Phillips TM. Chemokines released from astroglia by vasoactive intestinal peptide. Mechanism of neuroprotection from HIV envelope protein toxicity. Ann N Y Acad Sci 2000;921:109–14.
Frechilla D, Garcia-Osta A, Palacios S, Cenarruzabeitia E, Del Rio J. BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. Neuroreport 2001;12:919–23.
Onoue S, Ohshima K, Endo K, Yajima T, Kashimoto K. PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106–126. FEBS Lett 2002;522:65–70.
Falluel-Morel A, Aubert N, Vaudry D, Basille M, Fontaine M, Fournier A, et al. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem 2004;91:1231–43.
Deguil J, Chavant F, Lafay-Chebassier C, Pérault-Pochat MC, Fauconneau B, Pain S. Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotox Res 2010;17:142–55.
Reglodi D, Tamas A, Somogyvari-Vigh A, Szanto Z, Kertes E, Lenard L, et al. Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 2002;23:2227–34.
Gabryel B, Chalimoniuk M, Stolecka A, Waniek K, Langfort J, Malecki AJ. Inhibition of arachidonic acid release by cytosolic phospholipase A2 is involved in the antiapoptotic effect of FK506 and cyclosporin a on astrocytes exposed to simulated ischemia in vitro. Pharmacol Sci 2006;102:77–87.
Gabryel B, Łobuzek K, Małecki A, Herman ZS. Immunophilin ligands decreases release of pro-inflammatory cytokines (IL-1β, TNF-α and IL-2) in rat astrocytes cultures exposed to stimulated ischemia in vitro. Pol J Pharmacol 2004;56:129–36.
Ijichi A, Sakuma S, Tofioln PJ. Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures. Glia 1995;14:87–93.
Sinor AD, Irvin SM, Cobbs CS, Chen J, Graham SH, Greenberg DA. Hypoxic induction of vascular endothelial growth factor (VEGF) protein in astroglial cultures. Brain Res 1998;812:289–91.
Nito C, Ueda M, Inaba T, Katsura K, Katayama Y. FK506 ameliorates oxidative damage and protects rat brain following transient focal cerebral ischemia. Neurol Res 2011;33:881–9.
Saganová K, Gálik J, Blaško J, Korimová A, Račeková E, Vanický I. Immunosup-pressant FK506: focusing on neuroprotective effects following brain and spinal cord injury. Life Sci 2012;91:77–82.
Ebisu T, Mori Y, Katsuta K, Fujikawa A, Matsuoka N, Aoki I, et al. Neuroprotective effects of an immunosuppressant agent on diffusion/perfusion mismatch in transient focal ischemia. Magn Reson Med 2004;51:1173–80.
Zawadzka M, Kaminska B. A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells. Glia 2005;49:36–51.
Stumm R, Kolodziej A, Prinz V, Endres M, Wu DF, Höllt V. Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J Neurochem 2007;103:1666–81.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jóźwiak-Bębenista, M., Kowalczyk, E. & Nowak, J.Z. The cyclic AMP effects and neuroprotective activities of PACAP and VIP in cultured astrocytes and neurons exposed to oxygen-glucose deprivation. Pharmacol. Rep 67, 332–338 (2015). https://doi.org/10.1016/j.pharep.2014.10.001
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2014.10.001